blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1803441

EP1803441 - Pharmaceutical formulations of fenofibrate having improved bioavailability [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  05.03.2010
Database last updated on 13.11.2024
Most recent event   Tooltip07.10.2011Lapse of the patent in a contracting state
New state(s): CY		published on 09.11.2011  [2011/45]
Applicant(s)For all designated states
Teva Pharmaceutical Industries Ltd
5 Basel Street
PO Box 3190
49131 Petah Tiqva / IL
[N/P]
Former [2009/18]For all designated states
Teva Pharmaceutical Industries Ltd
5 Basel Street PO Box 3190
49131 Petah Tiqva / IL
Former [2007/27]For all designated states
Teva Pharmaceutical Industries Ltd
5 Basel Street PO Box 1390
49131 Petah Tiqva / IL
Inventor(s)01 / Lerner, Itzhak E.
Yahalom Street 18
Petach Tikva 49404 / IL
02 / Rosenberger, Vered
Migdal Hamenorah St. 16
Modiin, 71700 / IL
03 / Flashner-Barak, Moshe
Hefetz Mordechai 15
Petach Tikva 49313 / IL
04 / Drabkin, Anna
Netafim 5/1
Tzur Hadassa. 99875, P.O.B 10221 / IL
05 / Moldavski, Naomi
Moshav Dekel 36
D.N HaNegev, 85492 / IL
 [2007/27]
Representative(s)Gallagher, Kirk James, et al
D Young & Co LLP
120 Holborn
London EC1N 2DY / GB
[N/P]
Former [2007/27]Gallagher, Kirk James, et al
D Young & Co 120 Holborn
London EC1N 2DY / GB
Application number, filing date05258082.628.12.2005
[2007/27]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP1803441
Date:04.07.2007
Language:EN
[2007/27]
Type: B1 Patent specification 
No.:EP1803441
Date:29.04.2009
Language:EN
[2009/18]
Search report(s)(Supplementary) European search report - dispatched on:EP31.05.2006
ClassificationIPC:A61K9/14, A61K9/20, A61K31/216
[2007/27]
CPC:
A61K9/0007 (EP); A61K31/216 (EP); A61K9/1635 (EP);
A61K9/1694 (EP); A61K9/2027 (EP)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2007/27]
Extension statesAL20.01.2006
BA20.01.2006
HR20.01.2006
MK20.01.2006
YU20.01.2006
TitleGerman:Pharmazeutische Formulierungen mit Fenofibrat mit verbesserter Bioverfügbarkeit[2007/27]
English:Pharmaceutical formulations of fenofibrate having improved bioavailability[2007/27]
French:Formulation pharmaceutique comprenant du fénofibrate ayant une biodisponibilité ameliorée[2007/27]
Examination procedure20.01.2006Examination requested  [2007/27]
03.10.2006Amendment by applicant (claims and/or description)
22.02.2008Despatch of a communication from the examining division (Time limit: M04)
03.07.2008Reply to a communication from the examining division
19.11.2008Communication of intention to grant the patent
18.03.2009Fee for grant paid
18.03.2009Fee for publishing/printing paid
Opposition(s)01.02.2010No opposition filed within time limit [2010/14]
Fees paidRenewal fee
13.12.2007Renewal fee patent year 03
16.12.2008Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT29.04.2009
BE29.04.2009
CY29.04.2009
EE29.04.2009
LT29.04.2009
LV29.04.2009
SI29.04.2009
SK29.04.2009
BG29.07.2009
GR30.07.2009
LU28.12.2009
[2011/45]
Former [2011/21]AT29.04.2009
BE29.04.2009
EE29.04.2009
LT29.04.2009
LV29.04.2009
SI29.04.2009
SK29.04.2009
BG29.07.2009
GR30.07.2009
LU28.12.2009
Former [2010/52]AT29.04.2009
BE29.04.2009
EE29.04.2009
LT29.04.2009
LV29.04.2009
SI29.04.2009
SK29.04.2009
BG29.07.2009
GR30.07.2009
Former [2010/18]AT29.04.2009
BE29.04.2009
EE29.04.2009
LT29.04.2009
LV29.04.2009
SI29.04.2009
SK29.04.2009
BG29.07.2009
Former [2010/12]AT29.04.2009
BE29.04.2009
EE29.04.2009
LT29.04.2009
LV29.04.2009
SI29.04.2009
SK29.04.2009
Former [2010/01]AT29.04.2009
LT29.04.2009
LV29.04.2009
SI29.04.2009
Former [2009/51]AT29.04.2009
LT29.04.2009
SI29.04.2009
Former [2009/48]LT29.04.2009
Documents cited:Search[DA]US4895726  (CURTET BERNARD [FR], et al) [DA] 1-24 * column 1, line 4 - line 8 * * column 1, line 35 - column 2, line 4 * * examples 1-4 * * claims 1,2,4,6-12 *;
 [A]US2001006655  (CHEN YISHENG [US], et al) [A] 1-24 * paragraph [0009] * * paragraphs [0018] - [0020] * * examples 1-3 * * claims 1-15 *;
 [DX]US6277405  (STAMM ANDRE [FR], et al) [DX] 18-22,24 * column 1, line 11 - line 17 * * column 2, line 14 - line 31 * * column 3, line 29 - line 63 * * column 4, line 50 - line 60 * * examples 1-3; claims 1-7,10-13 *;
 [A]US2002056206  (PACE GARY W [US], et al) [A] 1-24 * paragraph [0001] * * paragraph [0080] * * paragraph [0089] * * paragraphs [0100] , [0101] * * paragraphs [0116] , [0117] * * examples 1-7 ** claims 1,11-13,15-17,28-34 *;
 [DX]US2003224059  (LERNER E ITZHAK [IL], et al) [DX] 18-22,24 * paragraphs [0014] - [0017] * * paragraphs [0021] - [0024] * * paragraph [0028] * * example 2 * * table 2 * * claims 1-20 *;
 [X]WO2005034920  (LIFECYCLE PHARMA AS [DK], et al) [X] 1-24 * page 1, line 4 - line 10 * * page 2, line 35 - page 3, line 8 * * page 6, line 6 - line 13 * * page 9, line 16 - line 20 * * page 24, line 13 - line 32 * * examples 1,3,6-8,10-12 * * claims 1-6,9,10,13-23,26,28,29,34,36,42,43,47-51,53-57,61; table 62 *
by applicantUS4895726
 US5827536
 US5880148
 US6074670
 US6277405
 US2003224059
 US6719999
 US2004087656
 US6814977
    - PHYSICIAN'S DESK REFERENCE, (2004), pages 522 - 525
    - PDR, MARTINDALE, page 889
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.